Home

Bisphenol A

BPA and Babies: New Research From FDA Focuses On What Happens In Womb

in

Forbes.com writer, Trevor Butterworth, looks at the bisphenol A (BPA) debate and finds that many media outlets neglect the complex studies coming out of regulatory agencies in favor of less scientific, overly simplistic studies advancing alarming health claims. He says “Not all scientific studies are created equal.” Butterworth interviews Daniel R.

FDA Publishes Survey of BPA and Infant Formula

in

International Formula Council Statement on FDA Survey of BPA and Infant Formula

The International Formula Council* (IFC) supports the U.S.

IFC Comments on Study Examining BPA and Human Placental Cells

in

A study in the December 2009 edition of Toxicology and Applied Pharmacology investigated toxic effects of BPA concentrations on human placental cells and concluded that low does of BPA “may cause detrimental effects, leading in vivo to adverse pregnancy outcomes such as preeclampsia, intrauterine growth restriction, prematurity and pregnancy loss.”* Although the study’s findings are interesting, the conclusions may be premature, as the study was performed in a cell culture model. The authors incubated isolated cells with BPA

BPA and the Developmental of Experimental Asthma in Mice

in

A study published in the February, 2009 edition of Environmental Health Perspectives suggested that perinatal exposure to BPA promotes the development of experimental asthma in a mice model, susceptible of asthma.* The researchers exposed fetal and neonatal mice to BPA via maternal loading and assessed pups’ response to allergic sensitization and bronchial challenge. 

 
The BPA e

Study Linking BPA to Heart Disease Has Limitations

in

A study in the January 2010 edition of Plos One, an online journal, titled, “Association of urinary bisphenol A concentration with heart disease: evidence from NHANES 2003/06” by Melzer et al.reports a statistical association between higher BPA levels and increased incidence of heart disease in the 2005-2006 National Health and Nutrition Examination Survey (NHANES) population.1 The authors conclude that “chance is an implausible explanation for the BPA association with heart disease.”  This report echoes findings published in 2008 in the Journal of the American Association (

BPA and Liquid Infant Formula Packaging

in

International Formula Council Statement on BPA and Liquid Infant Formula Packaging

On January 15, the U.S.

BPA in Premature Infants

in

Study Examining BPA Exposure in Premature Infants by Calfat et al.

A study by Calfat et al. published in the January 2009 edition of Environmental Health Perspectives describes a cross-sectional study in which urine samples from premature infants in two Boston-area hospitals were analyzed for free and total BPA and other compounds.1 This critique will focus only on the results pertaining to BPA. A total of 41 infants had at least one urine sample available for analysis of BPA and the authors were able to analyze both free and total BPA in 37 infants.

BPA Toxicokinetics

in

IFC Comments on Recent Mathematical Modeling study of BPA Toxicokinetics by Edginton and Ritter

Edington and Ritter present a mathematical model of the toxicokinetics of BPA and its glucuronidated metabolite, BPA-Glu, and estimate that the average steady state BPA plasma concentration in newborns is eleven times that in adults, when given the same weight-normalized dose.1  Additionally, they estimate by simulating typical feeding exposures, infants 3 and 6 months old show a five times greater steady state BPA plasma concentration when compared to adults. 

Infant Formula Safe and Healthy

in

Infant Formula Industry Reassures Parents that Infant Formulas Meet the Highest Safety Standards of Any Food Product on the Market

Testimony at FDA Science Board Hearing on BPA Reiterates Industry's Ongoing Commitment to Working with Regulatory Authorities to Protect the Health and Safety of Infants

WASHINGTON (Oct. 31, 2008) – The International Formula Council (IFC)*, testifying today along with other interested parties at the FDA Science Board meeting, expressed the infant formula industry’s support of science-based efforts to continually ensure that infant formulas meet the highest safety standards of any food product on the market.